Scott W. Andersen

4.8k total citations · 3 hit papers
65 papers, 3.0k citations indexed

About

Scott W. Andersen is a scholar working on Psychiatry and Mental health, Pharmacology and Physiology. According to data from OpenAlex, Scott W. Andersen has authored 65 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Psychiatry and Mental health, 27 papers in Pharmacology and 25 papers in Physiology. Recurrent topics in Scott W. Andersen's work include Alzheimer's disease research and treatments (24 papers), Treatment of Major Depression (18 papers) and Dementia and Cognitive Impairment Research (17 papers). Scott W. Andersen is often cited by papers focused on Alzheimer's disease research and treatments (24 papers), Treatment of Major Depression (18 papers) and Dementia and Cognitive Impairment Research (17 papers). Scott W. Andersen collaborates with scholars based in United States, United Kingdom and France. Scott W. Andersen's co-authors include Gary D. Tollefson, John R. Sims, Pierre V. Trân, Mark A. Mintun, Cynthia Evans, Sergey Shcherbinin, Alette M. Wessels, S.H. Hamilton, Amy J. Kuntz and Charles M. Beasley and has published in prestigious journals such as New England Journal of Medicine, PLoS ONE and Neurology.

In The Last Decade

Scott W. Andersen

62 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Donanemab in Early Alzheimer’s Disease

2021 969 citations Mark A. Mintun, Albert Lo et al. New England Journal of Medicine profile →
Double-Blind Comparison of Olanzapine Versus Risperidone in the Treatment of Schizophrenia and Other Psychotic Disorders

1997 567 citations Pierre V. Trân, S.H. Hamilton et al. Journal of Clinical Psychopharmacology profile →
Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease

2025 29 citations Jennifer A. Zimmer, Paul Ardayfio et al. JAMA Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Scott W. Andersen United States	21	1.8k	1.1k	812	348	282	65	3.0k
Hong Liu‐Seifert United States	25	1.5k 0.9×	1.7k 1.5×	1.0k 1.3×	411 1.2×	275 1.0×	53	3.6k
Gopalan Sethuraman United States	27	1.0k 0.6×	1.9k 1.7×	607 0.7×	668 1.9×	153 0.5×	61	3.8k
Elyse Stock United States	15	2.5k 1.4×	467 0.4×	334 0.4×	198 0.6×	131 0.5×	44	3.0k
Virginia L. Stauffer United States	30	2.3k 1.3×	427 0.4×	296 0.4×	153 0.4×	119 0.4×	85	2.7k
Yili Lu United States	19	1.2k 0.7×	832 0.7×	1.7k 2.1×	307 0.9×	109 0.4×	32	3.4k
Michael Case United States	25	1.4k 0.8×	775 0.7×	769 0.9×	152 0.4×	97 0.3×	63	2.2k
Lutz Froelich Germany	19	1.4k 0.8×	1.9k 1.7×	569 0.7×	777 2.2×	252 0.9×	54	3.9k
Edmond Teng United States	27	1.2k 0.7×	1.2k 1.0×	296 0.4×	324 0.9×	138 0.5×	80	2.6k
Michelle Gee United Kingdom	17	1.3k 0.8×	1.7k 1.5×	554 0.7×	763 2.2×	233 0.8×	26	3.8k
Douglas Galasko United States	27	1.5k 0.9×	1.7k 1.5×	332 0.4×	487 1.4×	136 0.5×	45	3.3k

Countries citing papers authored by Scott W. Andersen

Since Specialization

Citations

This map shows the geographic impact of Scott W. Andersen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott W. Andersen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott W. Andersen more than expected).

Fields of papers citing papers by Scott W. Andersen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott W. Andersen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott W. Andersen. The network helps show where Scott W. Andersen may publish in the future.

Co-authorship network of co-authors of Scott W. Andersen

This figure shows the co-authorship network connecting the top 25 collaborators of Scott W. Andersen. A scholar is included among the top collaborators of Scott W. Andersen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott W. Andersen. Scott W. Andersen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zimmer, Jennifer A., John R. Sims, Cynthia Evans, et al.. (2025). Donanemab in early symptomatic Alzheimer’s disease: results from the TRAILBLAZER-ALZ 2 long-term extension. The Journal of Prevention of Alzheimer s Disease. 13(2). 100446–100446.

Wang, Hong, Emel Serap Monkul Nery, Paul Ardayfio, et al.. (2025). The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6. The Journal of Prevention of Alzheimer s Disease. 12(8). 100266–100266. 2 indexed citations

Zimmer, Jennifer A., Paul Ardayfio, Hong Wang, et al.. (2025). Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease. JAMA Neurology. 82(5). 461–461. 29 indexed citations breakdown →

Fleisher, Adam, Leanne Munsie, David Pérahia, et al.. (2024). Assessment of Efficacy and Safety of Zagotenemab. Neurology. 102(5). e208061–e208061. 17 indexed citations

Willis, Brian A., Albert Lo, Jeffrey L. Dage, et al.. (2023). Safety, Tolerability, and Pharmacokinetics of Zagotenemab in Participants with Symptomatic Alzheimer’s Disease: A Phase I Clinical Trial. Journal of Alzheimer s Disease Reports. 7(1). 1015–1024. 8 indexed citations

Evans, Cynthia, JonDavid Sparks, Scott W. Andersen, et al.. (2023). APOE ε4's impact on response to amyloid therapies in early symptomatic Alzheimer's disease: Analyses from multiple clinical trials. Alzheimer s & Dementia. 19(12). 5407–5417. 8 indexed citations

Andersen, Scott W., et al.. (2023). HOMO-MEX: A Mexican Spanish Annotated Corpus for LGBT+phobia Detection on Twitter. 2 indexed citations

Holdridge, Karen C., R. Yaari, Deirdre B. Hoban, Scott W. Andersen, & John R. Sims. (2023). Targeting amyloid β in Alzheimer's disease: Meta‐analysis of low‐dose solanezumab in Alzheimer's disease with mild dementia studies. Alzheimer s & Dementia. 19(10). 4619–4628. 13 indexed citations

Mintun, Mark A., Albert Lo, Cynthia Evans, et al.. (2021). Donanemab in Early Alzheimer’s Disease. New England Journal of Medicine. 384(18). 1691–1704. 969 indexed citations breakdown →

10.

Andersen, Scott W., et al.. (2018). The Integrated Alzheimer's Disease Rating Scale (iADRS) Findings from the EXPEDITION3 Trial. The Journal of Prevention of Alzheimer s Disease. 5(2). 134–136. 14 indexed citations

11.

Shaw, Leslie M., Teresa Waligórska, Leona Fields, et al.. (2018). Derivation of cutoffs for the Elecsys^® amyloid β (1–42) assay in Alzheimer's disease. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring. 10(1). 698–705. 54 indexed citations

12.

Liu‐Seifert, Hong, Scott W. Andersen, Karen C. Holdridge, & Eric Siemers. (2015). Delayed-Start Analyses of Solanezumab Phase 3 Studies in Mild Alzheimer’s Disease (P7.108). Neurology. 84(14_supplement). 2 indexed citations

13.

Liu‐Seifert, Hong, Scott W. Andersen, Ilya Lipkovich, Karen C. Holdridge, & Eric Siemers. (2015). A Novel Approach to Delayed-Start Analyses for Demonstrating Disease-Modifying Effects in Alzheimer’s Disease. PLoS ONE. 10(3). e0119632–e0119632. 30 indexed citations

14.

Stauffer, Virginia L., Brian A. Millen, Scott W. Andersen, et al.. (2013). Pomaglumetad methionil: No significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo. Schizophrenia Research. 150(2-3). 434–441. 102 indexed citations

15.

Lauriello, John, Tim Lambert, Scott W. Andersen, et al.. (2008). An 8-Week, Double-Blind, Randomized, Placebo-Controlled Study of Olanzapine Long-Acting Injection in Acutely Ill Patients With Schizophrenia. The Journal of Clinical Psychiatry. 69(5). 790–799. 97 indexed citations

16.

Gureje, Oye, Nicholas A Keks, David Grainger, et al.. (2003). Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. Schizophrenia Research. 61(2-3). 303–314. 70 indexed citations

17.

Corya, S., Scott W. Andersen, Holland C. Detke, et al.. (2003). Long-Term Antidepressant Efficacy and Safety of Olanzapine/Fluoxetine Combination. The Journal of Clinical Psychiatry. 64(11). 1349–1356. 55 indexed citations

18.

Edgell, E.T., et al.. (2000). Olanzapine versus Risperidone. PharmacoEconomics. 18(6). 567–579. 57 indexed citations

19.

Tollefson, Gary D., Scott W. Andersen, & Pierre V. Trân. (1999). The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone. Biological Psychiatry. 46(3). 365–373. 68 indexed citations

20.

Trân, Pierre V., S.H. Hamilton, Amy J. Kuntz, et al.. (1997). Double-Blind Comparison of Olanzapine Versus Risperidone in the Treatment of Schizophrenia and Other Psychotic Disorders. Journal of Clinical Psychopharmacology. 17(5). 407–418. 567 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact